want to know more?
+31 (0)20 303 1970

drug discovery in the ubiquitin field

Access to well defined ubiquitinated peptides and conjugates, which could so far not be routinely produced (bio)chemically, is of paramount importance for screening assays for the identification of new drugs, as well as for fundamental research and structural studies. Find out about how our reagents enables research in the three stages of early drug discovery. 

target

Identify and validate your target using UbiQ Probes.

product info

lead

Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

product info

lead on target

Our reagents enable you in lead on target validation and lead optimization.

product info

reagents

about our products

UbiQ develops and commercializes ubiquitinated peptides, ubiquitin-based reagents and high throughput assays, which enable and expedite drug discovery in the rapidly expanding ubiquitin field. UbiQ, founded in 2010, is a spin-out of the Netherlands Cancer Institute (NKI), Amsterdam. 

view reagents    more info

custom made reagents

With our UbiQ technologies we are able to fully synthesize site-selective ubiquitinated peptides of native conformation, using automated solid phase peptide synthesis. This enables us to synthesize any custom made peptides.

news

  • UbiQ-news: Scientific accomplishments in 2019 and best wishes for 2020

    17 December 2019

    As we are near the end of this year, we would like to thank our worldwide scientific colleagues for their trust and collaborations. We are proud to be part of various exciting projects, and as such we have outlined below some important published insights which resulted from these collaborations...(more)

  • UbiQ-news: Antibody development by using monoubiquitinated peptides as antigens

    24 April 2019

    Conserved from yeast to human, the histone methyltransferase Dot1 methylates lysine 79 of histone H3 (H3K79) on the nucleosome core. This methylation affects gene expression and DNA damage response, and is enhanced by monoubiquitination of the C-terminus of histone H2B [1 - 4]. Given the promising clinical development of Dot1 inhibitors (e.g. for the treatment of acute leukemia in children [5]), it is important to elucidate the regulatory mechanisms of Dot1 [1 - 4].......(more)

     

  • UbiQ-news: Bio-orthogonally tagged activity-based probes for proteomics of deubiquitinating enzymes

    28 January 2019

    A recent paper in Nature Communications describes a collaborative effort between scientists at UbiQ, Genentech, Boston Biochem (Bio-Techne) and Stanford University (1). Here a reactive-site-centric chemoproteomics protocol is presented which allows evaluating activity and probe reactivity of deubiquitinating enzymes (DUBs, also termed deubiquitylases)......(more)

     

  • UbiQ-news: launch of an activity-based probe for the deubiquitinating enzyme OTULIN

    23 October 2017

    Hereby we present UbiQ-121 as an activity-based probe for OTULIN, a deubiquitinating enzyme that is specific for Met1 linked ubiquitin chains and acts as a negative regulator of nuclear factor κB signaling and immune homeostasis. UbiQ-121 is based on Met1 linked diubiquitin in which G76 of the distal ubiquitin is replaced by an electrophilic dehydroalanine (Dha) residue. The catalytic cysteine residue of OTULIN reacts in a covalent manner with the Dha residue and as such UbiQ-121 captures OTULIN in its active conformation .....(more)

     

© 2016 UbiQ Bio